Table 3. Monoclonal Antibodies (mAbs) with Emergency Use Authorization (EUA) or approved for use outside of the U.S.

mAb	Company	Stage	PDB	Target1	Publication2	Results2
Bamlanivimab	Lilly	EUA	7KMG	RBM II	31	220
Etesevimab	Lilly	EUA	7C01	RBM I	33	356
Casirivimab	Regeneron	EUA	6XDG	RBM I	45	408
Imdevimab	Regeneron	EUA	6XDG	RBD core	45	407
Sotrovimab	Vir	EUA	6WPS	RBD core	27	345
Tixagevimab	AstraZeneca	EUA	7L7D	RBM I	20	107
Cilgavimab	AstraZeneca	EUA	7L7E	RBM II	21	126
BRII-196	BRII Biosciences	China	7CDI	RBM I	7	198
BRII-198	BRII Biosciences	China	N/A	RBD core	4	94
Regdanivimab	Celltrion	South Korea	7CM4	RBM I	9	30

¹RBM (receptor binding motif) is the part of the receptor binding domain (RBD) that contains the spike ACE2 binding residues. RBM class 1 mAbs bind epitopes dominated by ACE2-binding residues and as a result bind solely when the RBD is in the up/open position. RBM class 2 mAbs have a smaller ACE2-binding footprint and can often bind the RBD in down/closed position. RBD core mAbs target a surface accessible part of the RBD that is separate from the RBM. ²The publications and results include those describing both in vitro selection and neutralization experiments.